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Abstract
Aims/hypothesis Lipids are a potent stimulus for the secretion
of glucagon-like peptide (GLP)-1 and glucose-dependent
insulinotropic peptide (GIP). Traditionally, this effect was
thought to involve the sensing of lipid digestion products by
free fatty acid receptor 1 (FFA1) and G-protein coupled recep-
tor 119 (GPR119) on the apical surface of enteroendocrine
cells. However, recent evidence suggests that lipids may in
fact be sensed basolaterally, and that fatty acid absorption
and chylomicron synthesis may be a prerequisite for their
stimulatory effect on gut peptide release. Therefore, we inves-
tigated the effect of chylomicrons onGLP-1 and GIP secretion
in vitro.
Methods The effect of chylomicrons on incretin secretion was
investigated using GLUTag cells and duodenal cultures of
both murine and human origin. The role of lipoprotein lipase
(LPL) and FFA1 in GLUTag cells was assessed by pharma-
cological inhibition and small (short) interfering RNA
(siRNA)-mediated knockdown. The effect of chylomicrons
on intracellular calcium concentration ([Ca2+]i) was deter-
mined by imaging GLUTag cells loaded with Fura-2. In the
primary setting, the contributions of FFA1 and GPR119 were
investigated using L cell-specific Gpr119 knockout cultures
treated with the FFA1 antagonist GW1100.
Results Chylomicrons stimulated GLP-1 release from
GLUTag cells, and both GLP-1 and GIP secretion from hu-
man and murine duodenal cultures. Chylomicron-triggered
GLP-1 secretion from GLUTag cells was largely abolished
following lipase inhibition with orlistat or siRNA-mediated
knockdown of Lpl. In GLUTag cells, both GW1100 and
siRNA-mediated Ffar1 knockdown reduced GLP-1 secretion
in response to chylomicrons, and, consistent with FFA1 Gq-
coupling, chylomicrons triggered an increase in [Ca2+]i.
However, LPL and FFA1 inhibition had no significant effect
on chylomicron-mediated incretin secretion in murine cul-
tures. Furthermore, the loss of GPR119 had no impact on
GLP-1 secretion in response to chylomicrons, even in the
presence of GW1100.
Conclusions/interpretation Chylomicrons stimulate incretin
hormone secretion from GLUTag cells as well as from human
andmurine duodenal cultures. In GLUTag cells, the molecular
pathway was found to involve LPL-mediated lipolysis, lead-
ing to the release of lipid species that activated FFA1 and
elevated intracellular calcium.
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Introduction
The upper small intestine harbours a rich population of
enteroendocrine cells (EECs) [1], which release gut peptides
following the ingestion of a meal. Lipids are an established
potent stimulus for the secretion of gut peptides including
incretins, glucagon-like peptide (GLP)-1 and glucose-
dependent insulinotropic peptide (GIP) [2–4]. These peptide
hormones serve to facilitate the efficient digestion and absorp-
tion of lipids and other nutrients, and to promote satiety.
However, despite significant advances in the field of intestinal
nutrient sensing in recent years, there are still gaps in our
understanding of the mechanisms underlying this fundamental
component of postprandial physiology.
Triacylglycerols are digested by lipases in the small intes-
tinal lumen to generate long-chain fatty acids (LCFAs) and 2-
monoacylglycerol. These digestion products mediate the stim-
ulatory effect of lipids on gut peptide secretion, acting via G-
protein-coupled receptors (GPCRs) expressed on EECs [5–7].
LCFAs are well-established agonists of the free fatty acid re-
ceptors 1 and 4 (FFA1 [GPR40] and FFA4 [GPR120]) [8–10].
Until recently, activation of these receptors was thought to
trigger gut peptide release solely via activation of Gq-coupled
intracellular pathways, as is indeed the case for the native
ligands, long-chain non-esterified fatty acids (NEFAs).
However, a new generation of synthetic ‘full’ FFA1 agonists
appears able to activate Gs-coupled signalling in addition to
Gq, and consequently yield greater secretory responses [11].
Monoacylglycerols on the other hand, in particular 2-
oleyolglycerol, are known to induce GLP-1 secretion by acti-
vating the Gs-coupled GPR119 receptor [12–14]. Secondary
messages downstream of GPCRs thus include elevation of
cytosolic Ca2+ and cAMP concentrations as well as activation
of protein kinases such as extracellular signal-regulated kinase
(ERK) [15].
Lipid-sensing receptors have traditionally been thought to
be expressed on the apical side of EECs and therefore, in the
‘classical’ model of intestinal fat-sensing, it is luminal lipid
digestion products that are responsible for receptor activation.
However, recent evidence has called into question the pres-
ence of FFA1 at least on the apical surface of EECs. Ex vivo
studies using isolated perfused rat intestine revealed that
linoleic acid and four synthetic FFA1 agonists elicited GLP-
1 secretion only when administered into the vasculature, and
not when administered directly into the gut lumen [16]. These
findings raise the possibility that FFA1 may actually reside on
the basolateral surface of EECs, and that fatty acid absorption
may be a prerequisite for lipid stimulated gut peptide release.
Fo l l ow ing the ab so rp t i on o f LCFAs and 2 -
monoacylglycerol by enterocytes, these are re-esterified into
triacylglycerols and packaged into chylomicrons.
Chylomicrons contain a central triacylglycerol-rich lipid core
(approximately 95% of the particle mass) and an outer layer
composed of phospholipids, apolipoproteins and non-
esterified cholesterol [17]. Mature chylomicrons are then traf-
ficked in vesicles to the basolateral surface of enterocytes,
from where they are released. At this point, chylomicrons
could interact with the basolateral surface of EECs. Indeed,
there is in vivo evidence in support of a role for chylomicron
formation and secretion in lipid-induced GLP-1 and GIP se-
cretion. When chylomicron formation was inhibited using the
surfactant Pluronic L81, the GLP-1 response to an
intraduodenal lipid emulsion in rats was significantly reduced
and the increase in GIP was practically abolished [18].
Therefore, we investigated the effect of chylomicrons on
GLP-1 and GIP secretion in vitro using GLUTag cells, an
established L cell model, as well as primary murine and hu-
man duodenal cultures. The mechanisms underlying this ef-
fect were explored by employing a combination of small
(short) interfering RNA (siRNA)-mediated genetic manipula-
tion and pharmacological inhibition.
Methods
Experimental animals and ethical approval
All animal procedures were approved by the University of
Cambridge Animal Welfare and Ethical Review Body and
conformed to the Animals (Scientific Procedures) Act 1986
Amendment Regulations (SI 2012/3039). The work was per-
formed under the UK Home Office Project License 70/7824.
Conditional Gpr119 knockout mice were generated by cross-
ing homozygous Gpr119 floxed mice with heterozygous
GLUCre12 mice, which express Cre recombinase under the
control of the proglucagon promoter, as previously described
[13]. All mice were on a C57BL/6 background and bred in
house. For secretion experiments, intestinal tissue was obtain-
ed from both male and female mice on a C57BL6 background
(aged 3–8 months). The mice were housed in individually
ventilated cages on a 12 h light/dark cycle with ad libitum
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access to water and regular chow. Mice were culled by ap-
proved schedule 1 methods.
RNA sequencing
High-quality total RNA extracted from approximately
10,000–12,000 FACS-purified L cells and 20,000 non-L cells
from the upper small intestine (top 10 cm) of GLU-Venus
mice [19] and 50,000 GLUTag cells (a gift from D. Drucker,
Lunenfeld-Tanenbaum Research Institute, Toronto, ON,
Canada) was used for sequencing, as previously described
[20]. Briefly, amplified cDNA was obtained using an
Ovation RNA-Seq System V2 (NuGEN, Leek, the
Netherlands) and used to generate barcoded libraries
(Ovation rapid DR Multiplex System 1-96; NuGEN) after
fragmentation to 200 bp. Libraries were SE50 sequenced
using an Illumina HiSeq 2500 system (Great Chesterford,
UK). After alignment to the mouse genome (GRCm38,
https://www.ncbi.nlm.nih.gov/grc/mouse), expression of
genes of interest in each sorted population (two positive ‘L
cell’ and two negative ‘non-L’ cell populations, and three
GLUTag passages) was determined using Cufflinks version
2.2.1 (http://cole-trapnell-lab.github.io/cufflinks/) and
expressed as fragments per kilobase per million reads
(FPKM).
Primary intestinal cultures
Murine Duodenal crypts were isolated and cultured as previ-
ously described [21] and recently demonstrated [22]. Briefly,
the duodenum (top 10 cm distal to the pylorus) was cleaned
thoroughly with ice-cold PBS and the muscle layer was re-
moved. The duodenum was cut open longitudinally and
minced using a surgical blade to produce tissue pieces of
around 1–2 mm2. The tissue pieces were then digested with
collagenase type XI (0.3 mg/ml high-glucose DMEM) at
37°C and filtered through a 100 μm cell strainer. The resulting
cell suspension was plated in a random order onto 24-well
plates coated with 2% Matrigel (BD Bioscience, Oxford,
UK) for the secretion experiments. The Rho-associated
coiled-coil containing protein kinase (ROCK) inhibitor
Y-27632 dihydrochloride (Tocris Bioscience, Bristol, UK)
was added to final cell suspensions at a concentration of
10 μmol/l to prevent anoikis.
Human The use of human intestinal tissue was approved by
the Cambridge Central Research Ethics Committee under li-
cense number 09/H0308/24. Fresh surgical specimens of
healthy human duodenum were obtained from the Tissue
Bank at Addenbrooke’s Hospital (Cambridge, UK). The tissue
was stored in L-15 (Leibovitz) medium (Sigma-Aldrich,
Poole, UK) at 4°C until processing (within a few hours of
surgery). The isolation and culture of mixed human duodenal
cells was performed using the same protocol as for murine
intestinal cultures, without the filtration step.
GLUTag cell culture
GLUTag cells, an established pro-glucagon-derived peptide-
secreting cell line model [23], were cultured as previously
described [24]. Cells for experimental use were plated onto
1% Matrigel-coated (BD BioScience) 24-well plates
(secretion) or 35 mm glass-bottomed plastic dishes (MatTek
Corporation, Ashland,MA, USA) (imaging). Secretion exper-
iments were carried out 18–24 h after plating. Imaging exper-
iments were carried out 18–48 h after plating.
siRNA knockdown
GLUTag cells in 24-well plates were transfected with
30 nmol/l AllStars negative control siRNA, Ffar1 siRNA
(Mm_Gpr40_2, target sequence: 5′-TGCGCTGGGCTTTC
CATTGAA-3′) or Lpl siRNA (Mm_Lpl_5, target sequence:
5 ′ -CAGCTCTATCTTGTTAGTTAA-3 ′ ) (Qiagen ,
Manchester, UK) using Lipofectamine 2000 (Thermo Fisher
Scientific, Loughborough, UK) as per the manufacturer’s pro-
tocol. Secretion experiments and RNA extraction (wells
transfected in parallel) were performed 48 h post-transfection.
Knockdown efficiency was assessed using TaqMan gene ex-
pression assays (see below).
Quantitative RT-PCR
Extraction of RNA from siRNA-treated GLUTag cells was
performed using an RNeasy Micro Kit (Qiagen). RNA
(500 ng) was reverse-transcribed using SuperScript II
(Thermo Fisher Scientific), and the resulting cDNA template
was mixed with PCR Master Mix (Thermo Fisher Scientific),
RNase-free water and specific TaqMan primers (Thermo
Fisher Scientific). All experiments were performed on isolated
cDNA samples from three independent transfection experi-
ments. In all cases, expression was compared with that of β-
actin measured from the same sample in parallel on the same
plate, giving a Ct difference (ΔCt) forβ-actin (Actb) minus the
test gene. Expression is calculated as 2ΔCt . The following
primer pairs were used (Thermo Fisher Scientific): Actb,
Mm02619580 ; Lp l , Mm00434764_m1 ; F fa r1 ,
Mm00809442_s1.
Ca2+ imaging
Imaging experiments using GLUTag cells were performed as
previously described [25]. Briefly, GLUTag cells were incu-
bated with 5 μmol/l Fura-2-acetoxymethyl-ester (Fura-2-AM;
Thermo Fisher Scientific, Waltham, MA, USA) and 1 mmol/l
glucose in assay buffer (see below) for 15 min at 37°C and
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15 min at room temperature. The Fura-2-AM solution was
then replaced with assay buffer. Cells loaded with Fura-2 were
continuously perfused with assay buffer with or without test
reagents, and changes in intracellular Ca2+ levels were
assessed by measuring the change in ratiometric fluorescence
(excitation 340/380 nm) at wavelength above 510 nm.
Experiments were performed using an Olympus IX71
inverted microscope with a 40× oil immersion objective, fitted
with a monochromator (Cairn Research, Faversham, UK) and
OrcaER camera (Hamamatsu, Hamamatsu City, Japan).
Images were acquired every 2 s and analysed, after back-
ground subtraction, using MetaFluor software (Molecular
Devices, Sunnyvale, CA, USA). Data were smoothened with
a 20 s sliding average. Maximum ratios were determined at
baseline (20 s prior to the test condition) and after test reagent
application. Cells were included in the analysis if they
responded to the positive control, 30 mmol/l KCl.
Approximately 15% of cells responded to chylomicrons, and
only the data from these cells (n = 44), termed ‘responders’ are
included in Fig. 1. Summary data are presented as mean cal-
culated increments (normalised to baseline).
Secretion studies
Cells were washed three times with assay buffer (see be-
low) and incubated with test reagents in assay buffer, sup-
plemented with 0.1% fatty acid-free BSA ± 10 mmol/l
glucose, for 2 h at 37°C. Test reagents were added in a
random order, which differed between experiments.
Supernatant and lysate samples were collected for primary
cell experiments and siRNA-treated GLUTag cells.
Supernatant samples only were collected for standard
GLUTag secretion experiments. Samples were assessed
using a total GLP-1 assay (Meso Scale Discovery,
Gaithersburg, MD, USA). GLP-1 measurement was
blinded. GIP was measured using a total GIP ELISA
(Millipore, Billerica, MA, USA). For standard GLUTag
secretion experiments, the raw GLP-1 data (in pg/ml) are
presented. For primary secretion experiments and siRNA-
treated GLUTag cells, hormone secretion was calculated as
a percentage of total hormone content per well, to account
for potential differences in EEC number between wells.
GLP-1 and GIP were measured in the same samples.
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Fig. 1 Chylomicrons stimulate GLP-1 secretion in GLUTag cells via an
increase in [Ca2+]i and activation of ERK signalling. (a) GLP-1 secretion
from GLUTag cells treated with chylomicrons in the presence of glucose
(10 mmol/l) with or without IBMX (100 μmol/l). Data represent means ±
SEM, n = 12–14 wells from four independent experiments; one-way
ANOVA, *p < 0.05, ***p < 0.001. (b) GLP-1 secretion from GLUTag
cells treated with glucose (10 mmol/l), chylomicrons (CM; 10 μg/ml) or
forskolin/IBMX (F/I; 10 μmol/l each) in the presence or absence of the
MEK inhibitor U0126 (10 μmol/l, following 30 min pre-treatment). Data
represent means ± SEM, n = 9 wells from three independent experiments
(apart from F/I, n = 6 wells from two independent experiments); one-way
ANOVA, ***p < 0.001. (c) Representative traces of the [Ca2+]i response
observed in GLUTag cells following application of chylomicrons (CM;
10 μg/ml) and the positive control KCl (30 mmol/l), added as indicated
by the horizontal bars. [Ca2+]i was monitored as the ratio of fluorescence
at 340 and 380 nm in individual GLUTag cells loaded with Fura-2. (d)
Mean 340/380-nm ratio averaged over 20 s periods. Data represent means
± SEM, n = 44 ‘responder’ cells; Friedman test with Dunn’s correction,
***p < 0.001 vs baseline
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Materials
All drugs and chemicals were purchased from Sigma-Aldrich
(UK), unless otherwise stated. Drugs were made up as 1000×
or 10,000× stock solutions, as per the manufacturer instruc-
tions. Human chylomicrons were obtained from BioVision
(Milpitas, CA, USA), and ten individual batches were used
during these studies. The broad-spectrum lipase inhibitor
orlistat was manufactured by Cayman Chemical (Ann Arbor,
MI, USA). The FFA1 agonist AM-1638 was kindly donated
by Lilly (Indianapolis, IN, USA). The FFA1 antagonist
GW1100 was manufactured by Merck Chemicals
(Nottingham, UK).
The assay buffer used in secretion and imaging experi-
ments contained (in mmol/l) 138 NaCl, 4.5 KCl, 4.2
NaHCO3, 1.2 NaH2PO4, 2.6 CaCl2, 1.2 MgCl2 and 10
HEPES (adjusted to pH 7.4 with NaOH).
Statistical analysis
Data are expressed as mean ± SEM unless otherwise indicat-
ed. Statistical analysis was performed using GraphPad Prism
5.00 software (San Diego, CA, USA). GLP-1 and GIP secre-
tion data were analysed by one-way ANOVAwith a post hoc
Bonferroni test (n ≥ 3 independent experiments performed in
duplicate or triplicate). For qRT-PCR data, statistical signifi-
cance between the expression of the target gene in siRNA-
treated vs negative control siRNA-treated GLUTag cells was
assessed by an independent t test (n = 3 independent experi-
ments performed in duplicate or triplicate). For the Ca2+ im-
aging experiments, statistical analysis was carried out using
raw baseline and treatment maximum 340/380-nm ratios
(n = 44 cells). As the data were not normally distributed and
the observations were paired, they were analysed using the
non-parametric Friedman test (p < 0.0001) with a Dunn’s post
hoc test for multiple comparisons.
Results
Effects of chylomicrons on GLP-1 secretion and [Ca2+]i
in GLUTag cells
Chylomicrons significantly increased GLP-1 secretion
from GLUTag cells (Fig. 1a; p < 0.05 vs control in the
presence of glucose; p < 0.001 vs control in the presence
of glucose/3-isobutyl-1-methylxanthine [IBMX]). As
ERK phosphorylation has previously been linked with
gut peptide release [26, 27], the ability of chylomicrons
to stimulate GLP-1 secretion was tested in the presence or
absence of the widely used mitogen-activated protein
kinase/ERK kinase (MEK) inhibitor U0126 (Fig. 1b).
Chylomicron-mediated GLP-1 secretion was significantly
impaired in GLUTag cells treated with U0126 (p < 0.001
vs untreated cells). Glucose-mediated GLP-1 secretion al-
so appeared to be affected by U0126, although this was
not consistently observed and therefore did not reach sta-
tistical significance. On the other hand, basal secretion
and GLP-1 secretion induced by forskolin/IBMX (a pre-
viously described robust stimulus) in the absence of glu-
cose were unaffected. Due to the coupling of intracellular
calcium ([Ca2+]i) elevations with gut peptide secretion,
the effect of chylomicrons on [Ca2+]i was also investigat-
ed. In a population of GLUTag cells (approximately
15%), application of chylomicrons triggered a significant
rise in [Ca2+]i (Fig. 1c, d).
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Fig. 2 Chylomicron-mediated GLP-1 release in GLUTag cells is depen-
dent on LPL. (a) Lpl expression was examined by RNA sequencing
FACS-sorted primary L cells (GLU-Venus-positive, L+) and negative
cells (GLU-Venus-negative, L−) collected in parallel from murine duo-
denum and GLUTag cells. FPKM, fragments per kilobase per million
reads. (b) GLP-1 secretion fromGLUTag cells treated with chylomicrons
(CM; 10 μg/ml) in the presence or absence of orlistat (1 μg/ml, following
30 min pre-treatment). Data represent means ± SEM, n = 9 wells from
three independent experiments; one-way ANOVA, ***p < 0.001. (c)
GLUTag cells were transfected with 30 nmol/l Lpl siRNA or negative
control (Ctrl) siRNA, and knockdown was validated by qRT-PCR. Data
are presented as means ± SEM, n = 5–6 from three independent experi-
ments; unpaired t test, **p < 0.01. (d) GLP-1 secretion from negative
control (white bars) or Lpl siRNA (grey bars) transfected GLUTag cells
treated with chylomicrons (CM; 10 μg/ml) or forskolin/IBMX (F/I;
10 μmol/l each) in the presence of glucose (10 mmol/l). Data represent
means ± SEM, n = 8–9 wells from three independent experiments; one-
way ANOVA, *p < 0.05, ***p < 0.001
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Dependence of chylomicron-mediated GLP-1 secretion
on lipoprotein lipase in GLUTag cells
To further dissect the mechanisms underlying chylomicron-
mediated GLP-1 secretion, genes of interest were identified
from an RNA-Seq database derived from duodenal GLU-
Venus-positive ‘L cells’ or negative control ‘non-L cells’, as
well as GLUTag cells. One gene that was identified as being
expressed in primary duodenal L cells and also highly
expressed in GLUTag cells was Lpl (Fig. 2a).
Treatment of GLUTag cells with the broad-spectrum lipase
inhibitor orlistat (tetrahydrolipstatin) [28] significantly
blunted chylomicron-induced GLP-1 secretion (Fig. 2b;
p < 0.001 vs untreated cells). To support these results,
GLUTag cells were also transfected with Lpl siRNA, or neg-
ative siRNA as a control. Post-transfection (48 h), a significant
knockdown of mRNA expression (approximately 90% reduc-
tion) was achieved (p < 0.01 vs negative siRNA), as deter-
mined by qRT-PCR (Fig. 2c). Secretion experiments using
these transfected cells demonstrated that GLP-1 release in
response to chylomicrons was practically abolished when
Lpl expression was knocked down (Fig. 2d). While there
was a significant difference in GLP-1 release following incu-
bation with the positive control forskolin/IBMX, this differ-
ence was no longer significant when expressed as ‘relative to
basal’, whereas the inhibition of chylomicron-stimulated se-
cretion remained significant (p < 0.001; data not shown).
Role of FFA1 in chylomicron-induced GLP-1 secretion
in GLUTag cells
As Ffar1 is known to be expressed by L cells and GLUTag
cells (Fig. 3a), we examined its role in potentially mediating
the effect of long-chain NEFAs, generated by chylomicron
hydrolysis, using the FFA1 antagonist GW1100. The synthet-
ic FFA1 selective agonist AM-1638 led to a significant in-
crease in GLP-1 secretion (p < 0.001 vs control) and was thus
used as a positive control. In the presence of GW1100, GLP-1
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Fig. 3 Chylomicrons stimulate GLP-1 release via FFA1 in GLUTag
cells. (a) FFA1 (Ffar1) expression was examined by RNA sequencing
FACS-sorted primary L cells (GLU-Venus-positive, L+) and negative
cells (GLU-Venus-negative, L−) collected in parallel from murine duo-
denum and GLUTag cells. FPKM, fragments per kilobase per million
reads. (b) GLP-1 secretion fromGLUTag cells treated with chylomicrons
(CM; 10 μg/ml) or the selective FFA1 agonist AM-1638 (1 μmol/l) in the
presence or absence of the FFA1 antagonist GW1100 (1 μmol/l, with
30 min pre-treatment). Data represent means ± SEM, n = 9 wells from
three independent experiments; one-way ANOVA, ***p < 0.001. (c)
GLUTag cells were transfected with 30 nmol/l Ffar1 siRNA or negative
control (Ctrl) siRNA, and knockdown was validated by qRT-PCR. Data
are presented as means ± SEM, n = 7 from three independent experi-
ments; unpaired t test, *p < 0.05. (d) GLP-1 secretion from negative
control (white bars) orFfar1 siRNA (grey bars) transfected GLUTag cells
treated with chylomicrons (CM; 10 μg/ml), AM-1638 (1 μmol/l) or
forskolin/IBMX (F/I; 10 μmol/l each) in the presence of glucose
(10 mmol/l). Data represent means ± SEM, n = 9 wells from three inde-
pendent experiments; one-way ANOVA, **p < 0.01, ***p < 0.001
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secretion in response to both AM-1638 and chylomicrons was
significantly inhibited in GLUTag cells (Fig. 3b).
To support these findings, GLUTag cells were also
transfected with Ffar1 siRNA or negative control siRNA.
Following transfection (48 h), Ffar1 expression was reduced
by approximately 50% (Fig. 3c, p < 0.05 vs negative siRNA).
GLP-1 secretion in response to both AM-1638 and chylomi-
crons was significantly inhibited in GLUTag cells transfected
with Ffar1 siRNA compared with negative siRNA (Fig. 3d;
p < 0.001 and p < 0.01, respectively). Basal secretion and the
response to forskolin/IBMX were unaltered by transfection
with Ffar1 siRNA.
Effects of chylomicrons on GLP-1 and GIP secretion
from human and murine primary intestinal cultures
To determine whether the stimulatory effect of chylomicrons
was maintained in primary cultures, GLP-1 and GIP secretion
was measured following incubation of duodenal cultures, of
both murine and human origin, with chylomicrons.
Chylomicrons at physiological concentrations of 10 and
100 μg/ml [29] significantly stimulated GLP-1 and GIP secre-
tion in murine duodenal cultures, in a dose-dependent fashion
(Fig. 4a, b). Furthermore, chylomicrons also led to a signifi-
cant increase in both GLP-1 and GIP secretion from human
duodenal cultures (Fig. 4c, d).
Mechanisms underlying chylomicron-mediated GLP-1
and GIP secretion from primary EECs
The relative contributions of FFA1 and GPR119 in
chylomicron-induced GLP-1 secretion were investigated using
duodenal cultures from conditional Gpr119 knockout mice
lacking GPR119 in proglucagon-expressing cells (Cre-posi-
tive/Gpr119flox), and the FFA1 antagonist GW1100. The ab-
sence of GPR119 in L cells did not impair GLP-1 release in
response to chylomicrons (Fig. 5a). However, it did prevent
GLP-1 secretion in response to the GPR119 agonist
AR231453 (Fig. 5a), which in the wild-type-like Cre-nega-
tive/Gpr119fl cultures significantly stimulated GLP-1 secretion
(Fig. 5b). As anticipated, the FFA1 agonist AM-1638 signifi-
cantly stimulated GLP-1 secretion in the primary cultures, an
effect that was inhibited by the FFA1 antagonist GW1100 (Fig.
5a, b). As GPR119 and FFA1 have been shown to act syner-
gistically [11, 14], we also tested the ability of chylomicrons to
stimulate GLP-1 secretion in a setting where both pathways
were inhibited, i.e. in L cell-specific Gpr119 knockout (Cre-
positive/Gpr119flox) cultures treated with GW1100. In the ab-
sence of bothGPR119 and FFA1 signalling, chylomicronswere
still able to significantly increase GLP-1 secretion (Fig. 5a).
To assess the role of FFA1 in mediating the stimulatory
effect of chylomicrons on GIP secretion, primary murine du-
odenal cultures were treated with chylomicrons (10 and
100 μg/ml) and AM-1638 in the presence or absence of
GW1100. As with GLP-1, the inhibition of FFA1 had no
effect on chylomicron-mediated GIP secretion from duodenal
cultures (Fig. 5c). Moreover, in our hands, AM-1638 did not
significantly stimulate GIP secretion (Fig. 5c).
Furthermore, treatment of duodenal cultures with the lipo-
protein lipase (LPL) inhibitor orlistat had no effect on
chylomicron-stimulated GLP-1 secretion (Fig. 5d).
Discussion
This study has demonstrated that chylomicrons, at physiolog-
ical concentrations [29], stimulate incretin hormone secretion
from GLUTag cells as well as from primary duodenal cultures
of both human and murine origin. In GLUTag cells, the mo-
lecular pathway was found to involve LPL-mediated lipolysis,
leading to the release of lipid species that activated FFA1 and
elevated intracellular calcium.
The importance of LPL in GLUTag cells was independent-
ly implicated by pharmacological inhibition and genetic
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Fig. 4 Chylomicrons stimulate GLP-1 and GIP secretion from human
and murine primary duodenal cultures. (a) GLP-1 and (b) GIP secretion
from murine duodenal cultures treated with chylomicrons (CM) in the
presence of glucose (10 mmol/l). Data represent means ± SEM, n = 12
wells (except for 100 μg/ml, n = 9 wells) from four independent exper-
iments; one-way ANOVA, *p < 0.05, ***p < 0.001. (c) GLP-1 and (d)
GIP secretion from human duodenal cultures treated with chylomicrons
or the positive control forskolin/IBMX (F/I; 10 μmol/l each) in the pres-
ence of glucose (10 mmol/l). Data represent means ± SEM, n = 9–10
wells (except for 10 μg/ml, n = 6 wells) from three independent experi-
ments; one-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001
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manipulation, as chylomicron-triggered GLP-1 secretion was
largely abolished following incubation with the broad-
spectrum lipase inhibitor orlistat [28] or siRNA-mediated
knockdown of Lpl mRNA expression. LPL catalyses the hy-
drolysis of chylomicron triacylglycerols to produce LCFAs
and monoacylglycerols, which are both well-known stimuli
of GLP-1 secretion acting via FFA1 and GPR119, respective-
ly. In GLUTag cells, both FFA1 antagonism using GW1100
[30] and siRNA-mediated Ffar1 knockdown reduced GLP-1
secretion in response to chylomicrons, and, consistent with the
known Gq-coupling of FFA1, chylomicrons triggered an in-
crease in intracellular Ca2+. The MEK inhibitor U0126 also
significantly inhibited chylomicron-triggered GLP-1 secre-
tion, suggesting an involvement of MEK–ERK signalling in
the secretory pathway downstream of chylomicrons.
Although ERK signalling has been implicated in the GLP-1
secretory response to a variety of stimuli [26, 27], how ERK
couples to secretion remains to be determined. Taken together,
these data suggest that in GLUTag cell cultures, chylomicrons
are hydrolysed by LPL to liberate LCFAs, which subsequently
activate FFA1 to trigger GLP-1 secretion. It is unclear whether
LPL adheres to the surface of GLUTag cells, potentially via
heparan sulphate proteoglycans, or whether it is secreted into
the medium, or indeed both.
Chylomicrons significantly stimulated both GLP-1 and
GIP secretion in human and murine duodenal cultures, con-
trasting with the findings of Chandra et al. [31], who reported
that chylomicrons at the same concentration (100μg/ml) stim-
ulated cholecystokinin (CCK) secretion only in the additional
presence of the fatty acid C12 (100 μmol/l), pointing towards
possible differences in the stimulus detection mechanisms for
CCK and incretin secretion. In primary intestinal cultures,
however, orlistat did not inhibit chylomicron-mediated GLP-
1 secretion, and no impairment of chylomicron-triggered
GLP-1 secretion was observed when the GPR119 and FFA1
pathways were inactivated. Although we cannot rule out the
possibility that orlistat was inactivated during the incubation
period [32], the additional lack of evidence for involvement of
GPR119 or FFA1 suggests that LPL-dependent hydrolysis of
triacylglycerols in chylomicrons does not underlie the stimu-
lation of GLP-1 and GIP secretion observed in primary cul-
tures. This is not the first demonstration of nutrients being
sensed via distinct mechanisms in GLUTag cells and primary
L cells (e.g. the role of GPRC6A in GLUTag cells but not
native L cells [33, 34]). As GLUTag cells were originally
derived from an intestinal tumour, it is conceivable that their
high expression of LPL may reflect a cancerous phenotype.
LPL has been detected in a number of tumour types and has
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Fig. 5 FFA1 does not play a role in chylomicron-mediated GLP-1 and
GIP secretion in murine primary cultures. (a) GLP-1 secretion from L
cell-specific Gpr119 knockout (Cre-positive/Gpr119flox) and (b) wild-
type-like (Cre-negative/Gpr119flox) murine duodenal cultures treated
with the GPR119 agonist AR231453 (AR; 100 nmol/l), chylomicrons
(CM; 100 μg/ml) or the FFA1 agonist AM-1638 (1 μmol/l), in the pres-
ence or absence of the FFA1 antagonist GW1100 (5 μmol/l, 30 min pre-
treatment). Data represent means ± SEM, n = 9 wells from three indepen-
dent experiments; one-way ANOVA, **p < 0.01, ***p < 0.001 vs glu-
cose (10 mmol/l) control. (c) GIP secretion from murine duodenal
cultures treated with chylomicrons (CM; 10 or 100 μg/ml) or AM-1638
(1 μmol/l), in the presence or absence of GW1100 (5 μmol/l, 30 min pre-
treatment). Data represent means ± SEM, n = 11–21 wells from 4–7
independent experiments; one-way ANOVA, **p < 0.01 vs glucose
(10 mmol/l) control. (d) GPL-1 secretion from murine duodenal cultures
treated with chylomicrons (CM; 100μg/ml), in the presence or absence of
orlistat (10 μg/ml, 30 min pre-treatment). Data represent means ± SEM,
n = 11–12 wells from four independent experiments; one-way ANOVA,
***p < 0.001 vs glucose (10 mmol/l) control
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been shown to be critical in enabling cancer cells to acquire
NEFAs from culture medium [35].
Given that lipolysis does not appear to be required for
chylomicron-dependent GLP-1 secretion from primary intes-
tinal cultures, it is possible that this effect is mediated by a
lipoprotein or scavenger receptor expressed by primary L
cells. Chandra et al. [31] found that CCK secretion in response
to the combination of HDL and C12 was significantly
inhibited in I cells lacking the ILDR1 receptor. However,
CCK release in response to the combination of chylomicrons
and C12 was not significantly reduced by ILDR1 deficiency,
suggesting the involvement of an additional pathway for chy-
lomicron sensing. This might involve the detection of mole-
cules on the chylomicron surface, or of other lipid species
released from the chylomicron core. Interestingly, apolipopro-
tein A-IV, present on the surface of chylomicrons, has been
implicated in the suppression of gastric motility and food in-
take, via an increase in CCK secretion [36, 37], as well as in
glucose homeostasis via an increase in insulin secretion [38].
However, a specific receptor for apolipoprotein A-IV has yet
to be identified, and purified human apolipoprotein A-IV or
apolipoprotein A-I failed to stimulate GLP-1 secretion in pri-
mary murine epithelial cultures (see electronic supplementary
material [ESM] Fig. 1). As the preservation of the apical/
basolateral polarisation and limited access to only the
basolateral compartment are compromised in primary epithe-
lial cultures, we cannot exclude that the observed stimulation
by chylomicrons is a result of artificial access to apically lo-
cated receptors; however, we can exclude GPR119 and FFA1
as possible mediators under these culture conditions, as
discussed above. By contrast, we cannot exclude apolipopro-
tein A-I or A-IV as possible mediators, as the results of the
pilot experiments might simply reflect conformational chang-
es due to the purification of the apolipoproteins.
The release of gut peptides in response to chylomicrons
may have physiological relevance beyond the classical
slowing of gastrointestinal motility and increase in satiety. In
addition to producing GLP-1, primary L cells also produce
GLP-2, from the processing of the proglucagon precursor.
GLP-2 is best known for its role in stimulating intestinal
growth and promoting nutrient absorption [39, 40], including
fat absorption via an upregulation of CD36/fatty acid
translocase [41]. Intriguingly, there is emerging evidence to
suggest that GLP-2 also promotes the release of preformed
chylomicrons from enterocytes in humans and animal models
[42, 43], an effect that under normal physiological conditions
is thought to predominate over the opposing action of GLP-1
[44]. The mechanisms underlying this effect are currently un-
clear and are presumably indirect, given that neither the GLP-
1 nor the GLP-2 receptor is thought to be expressed by
enterocytes.
The idea that chylomicron formation is important for EEC
detection of ingested lipids was suggested previously by
in vivo experiments in rats, which demonstrated that co-
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Fig. 6 Schematic of proposed
revised model of intestinal fat
sensing. Rather than stimulating
GLP-1 secretion through apically
located long-chain NEFA- and/or
monoacylglycerol-sensing
receptors, we propose the re-
esterification and secretion of
chylomicrons from enterocytes to
be an essential step in lipid-
sensing of intestinal L cells. LPL
expressed either by L cells or
other cells within the villus core
sufficiently hydrolyses
triacylglycerols to stimulate
basolaterally located FFA1. The
results in primary mixed epithelial
cultures suggest additional
sensing mechanisms independent
of triacylglycerol hydrolysis
through yet to be identified
receptors (‘ApoR’). 2-MAG, 2-
monoacylglycerol
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administration of an intraduodenal lipid emulsion with
Pluronic L-81, an inhibitor of chylomicron formation [45,
46], significantly impaired GLP-1 secretion and largely
abolished GIP secretion [18]. Other in vivo studies have
shown that oral lipid-triggered GLP-1 and GIP secretion is
strongly dependent on FFA1 and GPR119, and that FFA1 on
L cells responds primarily to ligands delivered from the
basolateral direction [13, 14, 16]. Our results from murine
and human cultures demonstrating an effect of chylomicrons
on gut hormone secretion and the molecular pathway
highlighted in GLUTag cells could explain a wealth of these
in vivo findings.
This model (Fig. 6) involves a chylomicron-dependent step
for delivery of lipids to the basolateral compartment of the
intestinal epithelium, followed by the local lipase-dependent
production of active lipid species such as LCFAs and
monoacylglycerols, which target GPCRs such as FFA1 and
GPR119 on the basolateral membrane of EECs and thereby
stimulate gut peptide secretion. Although we could not dem-
onstrate the validity of this molecular pathway in the primary
duodenal culture model, we do not believe this rules out the
possibility that the pathway plays an important role in the
intact gut, where other non-epithelial cells lost in the cultures
might contribute to partial chylomicron lipolysis. Therefore,
further work is warranted to establish the importance of local
lipase-dependent LCFA and monoacylglycerol delivery from
chylomicrons for the stimulation of gut hormone release by
ingested lipids.
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